Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Falzarano D, Feldmann H.

Curr Opin Virol. 2013 Jun;3(3):343-51. doi: 10.1016/j.coviro.2013.04.007. Epub 2013 Jun 15. Review.

2.

Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.

Martinez-Sobrido L, de la Torre JC.

Expert Rev Vaccines. 2016 Sep;15(9):1113-21. doi: 10.1080/14760584.2016.1182024. Epub 2016 May 13. Review.

3.

Vaccine platforms to control Lassa fever.

Lukashevich IS, Pushko P.

Expert Rev Vaccines. 2016 Sep;15(9):1135-50. doi: 10.1080/14760584.2016.1184575. Epub 2016 May 24. Review.

PMID:
27136941
4.

Recent advances in vaccines against viral haemorrhagic fevers.

Baize S, Marianneau P, Georges-Courbot MC, Deubel V.

Curr Opin Infect Dis. 2001 Oct;14(5):513-8. Review.

PMID:
11964870
6.

Novel approaches to develop Rift Valley fever vaccines.

Indran SV, Ikegami T.

Front Cell Infect Microbiol. 2012 Oct 26;2:131. doi: 10.3389/fcimb.2012.00131. eCollection 2012. Review.

7.

Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Olschläger S, Flatz L.

PLoS Pathog. 2013;9(4):e1003212. doi: 10.1371/journal.ppat.1003212. Epub 2013 Apr 11. Review.

8.

Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.

Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, Garry RF.

Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279.

9.

Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of Rift Valley fever in Borno State, Nigeria.

Bukbuk DN, Fukushi S, Tani H, Yoshikawa T, Taniguchi S, Iha K, Fukuma A, Shimojima M, Morikawa S, Saijo M, Kasolo F, Baba SS.

Trans R Soc Trop Med Hyg. 2014 Dec;108(12):768-73. doi: 10.1093/trstmh/tru163. Epub 2014 Oct 24.

PMID:
25344695
10.

Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Terasaki K, Tercero BR, Makino S.

Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27. Review.

11.

Viral haemorrhagic fevers. Report of a WHO Expert Committee.

[No authors listed]

World Health Organ Tech Rep Ser. 1985;721:5-126. No abstract available.

PMID:
2867649
12.

[Viral hemorrhagic fever].

Kager PA.

Ned Tijdschr Geneeskd. 1998 Feb 28;142(9):448-51. Review. Dutch.

PMID:
9562757
13.

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.

Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H.

PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736. doi: 10.1371/journal.pntd.0003736. eCollection 2015 Apr.

14.

Viral hemorrhagic fevers.

Lacy MD, Smego RA.

Adv Pediatr Infect Dis. 1996;12:21-53. Review. No abstract available.

PMID:
9033974
15.

One Health approach to Rift Valley fever vaccine development.

Kortekaas J.

Antiviral Res. 2014 Jun;106:24-32. doi: 10.1016/j.antiviral.2014.03.008. Epub 2014 Mar 26. Review.

PMID:
24681125
16.

[The vaccines based on the replicon of the venezuelan equine encephalomyelitis virus against viral hemorrhagic fevers].

Petrov AA, Plekhanova TM, Sidorova ON, Borisevich SV, Makhlay AA.

Vopr Virusol. 2015;60(3):14-8. Review. Russian.

PMID:
26281301
17.

[Viral hemorrhagic fever--Ebola hemorrhagic fever, Marburg disease and Lassa fever].

Hotta H.

Rinsho Byori. 1998 Jul;46(7):651-5. Review. Japanese.

PMID:
9721531
18.

Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps.

Kerber R, Reindl S, Romanowski V, Gómez RM, Ogbaini-Emovon E, Günther S, ter Meulen J.

J Clin Virol. 2015 Mar;64:120-7. doi: 10.1016/j.jcv.2014.12.004. Epub 2014 Dec 18. Review.

PMID:
25549822
19.

Animal models of viral hemorrhagic fever.

Smith DR, Holbrook MR, Gowen BB.

Antiviral Res. 2014 Dec;112:59-79. doi: 10.1016/j.antiviral.2014.10.001. Epub 2014 Oct 18. Review.

PMID:
25448088
20.

Advances in virus-like particle vaccines for filoviruses.

Warfield KL, Aman MJ.

J Infect Dis. 2011 Nov;204 Suppl 3:S1053-9. doi: 10.1093/infdis/jir346. Review.

Supplemental Content

Support Center